Verona Pharma plc
VRNA
VRNA: Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma. The company is engaged in pharmaceutical development.
moreShow VRNA Financials
Recent trades of VRNA by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by VRNA's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: Salt of a pyrimido[6,1-a]isoquinolin-4-one compound Nov. 08, 2022
-
Patent Title: Liquid inhalation formulation comprising rpl554 Mar. 16, 2021
-
Patent Title: Treatment Dec. 15, 2020
-
Patent Title: Compound and process Jul. 14, 2020
-
Patent Title: Drug combination of pde3/pde4 inhibitor and muscarinic receptor antagonist Nov. 12, 2019
-
Patent Title: Salt of a pyrimido[6,1-a]isoquinolin-4-one compound Nov. 05, 2019
-
Patent Title: Liquid inhalation formulation comprising rpl554 May. 01, 2018
-
Patent Title: Drug combination Aug. 01, 2017
-
Patent Title: Drug combination of pde3/pde4 inhibitor and muscarinic receptor antagonist Jul. 11, 2017
-
Patent Title: Crystalline form of pyrimido[6,1-a] isoquinolin-4-one compound Jun. 23, 2015
-
Patent Title: Derivatives of pyrimido[6,1-a]isoquinolin-4-one Aug. 14, 2012
Federal grants, loans, and purchases
Followers on VRNA's company Twitter account
Number of mentions of VRNA in WallStreetBets Daily Discussion
Recent insights relating to VRNA
Recent picks made for VRNA stock on CNBC
ETFs with the largest estimated holdings in VRNA
Flights by private jets registered to VRNA